Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

, RHHBY

Roche

$30.83

0.13 (0.42%)

08:33
10/06/16
10/06
08:33
10/06/16
08:33

Kite Pharma initiates phase 1b/2 combination study for KTE-C19, atezolizumab

Kite Pharma (KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma. PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group (RHHBY), to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab. The first ZUMA-6 patient was enrolled at the end of September 2016.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

RHHBY

Roche

$30.83

0.13 (0.42%)

  • 07

    Oct

  • 18

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

KITE Kite Pharma
$56.41

1.57 (2.86%)

09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Kite Pharma data positive, says RBC Capital
RBC Capital analyst Michael Yee says that Kite reported positive Phase II data for its KTE-C19 drug in DLBCL with a 47% complete response rate which beat expectations. The analyst says that the complete response rate "is very supportive of FDA approval." He keeps an Outperform rating on the shares.
09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
RHHBY Roche
$30.83

0.13 (0.42%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

APRN

Blue Apron

$5.47

0.28 (5.40%)

14:45
09/25/17
09/25
14:45
09/25/17
14:45
Options
Blue Apron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

, PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

14:42
09/25/17
09/25
14:42
09/25/17
14:42
Hot Stocks
Analysts trim TripAdvisor estimates on increasing online travel concerns »

Shares of TripAdvisor…

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

TRVG

trivago

$10.70

-0.04 (-0.37%)

EXPE

Expedia

$145.77

2.65 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.51

-1.185 (-1.43%)

14:36
09/25/17
09/25
14:36
09/25/17
14:36
Conference/Events
Dycom management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

DY

Dycom

$81.56

-1.13 (-1.37%)

14:35
09/25/17
09/25
14:35
09/25/17
14:35
Options
Dycom put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

14:31
09/25/17
09/25
14:31
09/25/17
14:31
Technical Analysis
Technical View: Amazon.com falls, topping process confirmed »

The shares are down 2.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DIS

Disney

$99.37

0.77 (0.78%)

14:27
09/25/17
09/25
14:27
09/25/17
14:27
Recommendations
Disney analyst commentary  »

Disney approach to price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ESV

Ensco

$5.77

0.53 (10.11%)

14:25
09/25/17
09/25
14:25
09/25/17
14:25
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

NFLX

Netflix

$187.35

-1.43 (-0.76%)

14:21
09/25/17
09/25
14:21
09/25/17
14:21
Technical Analysis
Technical View: Netflix trades near lows of the day »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

14:17
09/25/17
09/25
14:17
09/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/25/17
09/25
14:16
09/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GREK

Global X MSCI Greece ETF

$9.18

-0.635 (-6.47%)

14:10
09/25/17
09/25
14:10
09/25/17
14:10
Options
MSCI Greek Fund puts are active as shares falter »

MSCI Greek Fund puts are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.30

-0.11 (-0.82%)

, NVDA

Nvidia

$179.00

-1.76 (-0.97%)

14:08
09/25/17
09/25
14:08
09/25/17
14:08
Hot Stocks
AMD, NVIDIA fall after Intel unveils next generation of core processors »

Shares of AMD (AMD) and…

AMD

AMD

$13.30

-0.11 (-0.82%)

NVDA

Nvidia

$179.00

-1.76 (-0.97%)

INTC

Intel

$37.18

-0.02 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

  • 22

    Oct

HLF

Herbalife

$67.51

-0.06 (-0.09%)

14:06
09/25/17
09/25
14:06
09/25/17
14:06
Hot Stocks
FTC grants Carl Icahn clearance for additional Herbalife purchases »

The Federal Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$80.52

4.45 (5.85%)

14:05
09/25/17
09/25
14:05
09/25/17
14:05
Options
YY call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
09/25/17
09/25
14:05
09/25/17
14:05
General news
Treasury Option Action: heavy put spread demand at the short-end »

Treasury Option Action:…

RCII

Rent-A-Center

$10.80

-0.07 (-0.64%)

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Options
Rent A Center put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Conference/Events
Senate Finance Committee holds a hearing »

The Committee holds a…

GS

Goldman Sachs

$230.10

-0.93 (-0.40%)

13:54
09/25/17
09/25
13:54
09/25/17
13:54
Periodicals
Symphony to raise $100M to expand, The Information says »

Goldman Sachs-backed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

AMDA

Amedica

$0.33

0.005 (1.56%)

13:50
09/25/17
09/25
13:50
09/25/17
13:50
Downgrade
Amedica rating change  »

Amedica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SCWX

SecureWorks

$12.57

0.15 (1.21%)

13:47
09/25/17
09/25
13:47
09/25/17
13:47
Hot Stocks
Breaking Hot Stocks news story on SecureWorks »

ETF Managers Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$36.59

0.81 (2.26%)

13:45
09/25/17
09/25
13:45
09/25/17
13:45
Options
Devon Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

13:45
09/25/17
09/25
13:45
09/25/17
13:45
General news
Treasury Action: coupon supply commences Tuesday »

Treasury Action: coupon…

ADP

ADP

$108.16

1.37 (1.28%)

13:43
09/25/17
09/25
13:43
09/25/17
13:43
Hot Stocks
Pershing: ADP overstates shareholder return during CEO's tenure »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIEGY

Siemens

$69.77

-0.4307 (-0.61%)

, ALSMY

Alstom

$3.95

0.202 (5.39%)

13:40
09/25/17
09/25
13:40
09/25/17
13:40
Periodicals
Siemens, Alstom finalizing rail merger details, Bloomberg says »

According to people…

SIEGY

Siemens

$69.77

-0.4307 (-0.61%)

ALSMY

Alstom

$3.95

0.202 (5.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMDA

Amedica

$0.33

0.005 (1.56%)

13:37
09/25/17
09/25
13:37
09/25/17
13:37
Downgrade
Amedica rating change  »

Amedica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.